PBDA Stock Chart & Stats
€2.20
€0.00(0.00%)
At close: 4:00 PM EDT
€2.20
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.29 - €2.66
Previous CloseN/A
Volume0.00
Average Volume (3M)25.00
Market Cap
€176.64M
Enterprise Value€160.20
Total Cash (Recent Filing)€27.42M
Total Debt (Recent Filing)€9.21M
Price to Earnings (P/E)10.5
Beta0.98
Next Earnings
Nov 16, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding80,571,640
10 Day Avg. Volume0
30 Day Avg. Volume25
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.93
Price to Sales (P/S)2.68
P/FCF Ratio-10.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)€68.60M
Bulls Say, Bears Say
Bulls Say
Improved Profitability And Cash GenerationTTM profitability and cash generation indicate the commercial business can currently fund operations, while strong gross and operating margins provide a buffer. The sharp improvement from 2025 establishes a stronger base for continued investment.
Elfabrio Commercial Growth And Market AccessGrowing Elfabrio sales and broader dosing and geographic approvals can expand patient access and partner demand. These regulatory and commercial gains strengthen the product’s market position and support a longer-term revenue platform.
Debt-free Balance Sheet And LiquidityA debt-free balance sheet and substantial liquid resources reduce financing risk and preserve flexibility. Protalix can use this capacity to sustain operations, advance its pipeline and absorb development volatility without immediate leverage pressure.
Bears Say
Partner Concentration And Non-recurring RevenueDependence on Chiesi and uneven purchasing can make reported revenue difficult to forecast. The large milestone also boosted H1 results without representing recurring product demand, raising durability risk for future growth comparisons.
PRX-115 Immunogenicity And Regimen UncertaintyHigh observed immunogenicity and unresolved dosing choices could limit PRX-115’s clinical profile, delay advancement or require additional development work. This creates meaningful uncertainty around the pipeline’s future contribution.
Volatile And Potentially Unsustainable Cash ConversionPositive current cash generation is not yet consistently demonstrated across periods. Historical cash-flow losses and the recent decline reduce confidence that reported profitability will reliably translate into durable funding for research and operations.
Protalix News
PBDA FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was €1.29 and its highest was €2.66 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Protalix Biotherapeutics’s market cap is €176.64M.
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 78 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on Aug 12, 2026. The company reported €0.043 earnings per share for the quarter, beating the consensus estimate of -€0.009 by €0.052.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Overvalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate is -0.02.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 80,571,640 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of €0.043 in its last earnings report, beating expectations of -€0.009. Following the earnings report the stock price went up 7.637%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Currently, no hedge funds are holding shares in DE:PBDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protalix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
40.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Protalix Biotherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
PBDA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented several strong operational and financial positives — double-digit quarterly revenue growth, a >100% year-to-date revenue increase, meaningful Q2 net income, strong Elfabrio commercial momentum with regulatory and patent tailwinds, a solid cash position and advancing pipeline (PRX-115 with topline expected H2 2027). Offsetting risks include quarter-to-quarter revenue lumpiness and partner concentration (Chiesi), a reliance on a one-time $25M milestone in H1, increased cost of revenues and taxes, and clinical uncertainties around immunogenicity and regimen selection for PRX-115. Overall, the positives — particularly the robust revenue growth, improved profitability and cash position — outweigh the noted risks, though sustainability and immunogenicity remain items to monitor.View all DE:PBDA earnings summariesTechnical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
Forte Biosciences
―
Innate Pharma
―